Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 148
Filtrer
1.
J Am Chem Soc ; 146(26): 17747-17756, 2024 Jul 03.
Article de Anglais | MEDLINE | ID: mdl-38889317

RÉSUMÉ

Unveiling molecular mechanisms that dominate protein phase dynamics has been a pressing need for deciphering the intricate intracellular modulation machinery. While ions and biomacromolecules have been widely recognized for modulating protein phase separations, effects of small molecules that essentially constitute the cytosolic chemical atmosphere on the protein phase behaviors are rarely understood. Herein, we report that vitamin C (VC), a key small molecule for maintaining a reductive intracellular atmosphere, drives reentrant phase transitions of myosin II/F-actin (actomyosin) cytoskeletons. The actomyosin bundle condensates dissemble in the low-VC regime and assemble in the high-VC regime in vitro or inside neuronal cells, through a concurrent myosin II protein aggregation-dissociation process with monotonic VC concentration increase. Based on this finding, we employ in situ single-cell and single-vesicle electrochemistry to demonstrate the quantitative modulation of catecholamine transmitter vesicle exocytosis by intracellular VC atmosphere, i.e., exocytotic release amount increases in the low-VC regime and decreases in the high-VC regime. Furthermore, we show how VC regulates cytomembrane-vesicle fusion pore dynamics through counteractive or synergistic effects of actomyosin phase transitions and the intracellular free calcium level on membrane tensions. Our work uncovers the small molecule-based reversive protein phase regulatory mechanism, paving a new way to chemical neuromodulation and therapeutic repertoire expansion.


Sujet(s)
Actines , Acide ascorbique , Exocytose , Acide ascorbique/composition chimique , Acide ascorbique/pharmacologie , Exocytose/effets des médicaments et des substances chimiques , Actines/métabolisme , Actines/composition chimique , Transition de phase , Animaux , Myosine de type II/métabolisme , Myosine de type II/antagonistes et inhibiteurs , Techniques électrochimiques , Actomyosine/métabolisme , Actomyosine/composition chimique , Rats
2.
ACS Chem Biol ; 16(11): 2164-2173, 2021 11 19.
Article de Anglais | MEDLINE | ID: mdl-34558887

RÉSUMÉ

Myosin IIs, actin-based motors that utilize the chemical energy of adenosine 5'-triphosphate (ATP) to generate force, have potential as therapeutic targets. Their heavy chains differentiate the family into muscle (skeletal [SkMII], cardiac, smooth) and nonmuscle myosin IIs. Despite the therapeutic potential for muscle disorders, SkMII-specific inhibitors have not been reported and characterized. Here, we present the discovery, synthesis, and characterization of "skeletostatins," novel derivatives of the pan-myosin II inhibitor blebbistatin, with selectivity 40- to 170-fold for SkMII over all other myosin II family members. In addition, the skeletostatins bear improved potency, solubility, and photostability, without cytotoxicity. Based on its optimal in vitro profile, MT-134's in vivo tolerability, efficacy, and pharmacokinetics were determined. MT-134 was well-tolerated in mice, impaired motor performance, and had excellent exposure in muscles. Skeletostatins are useful probes for basic research and a strong starting point for drug development.


Sujet(s)
Composés hétérocycliques avec 4 noyaux ou plus/composition chimique , Myosine de type II/antagonistes et inhibiteurs , Animaux , Souris , Structure moléculaire , Muscles squelettiques/métabolisme , Myosine de type II/métabolisme , Myosine de type II/toxicité
3.
PLoS One ; 16(8): e0255656, 2021.
Article de Anglais | MEDLINE | ID: mdl-34343209

RÉSUMÉ

Although quiescent hepatic stellate cells (HSCs) have been suggested to regulate hepatic blood flow, there is no direct evidence that quiescent HSCs display contractile abilities. Here, we developed a new method to quantitatively measure the contraction of single isolated HSCs and evaluated whether endothelin-1 (ET-1) induced contraction of HSCs in a non-activated state. HSCs isolated from mice were seeded on collagen gel containing fluorescent beads. The beads around a single HSC were observed gravitating toward the cell upon contraction. By recording the movement of each bead by fluorescent microscopy, the real-time contraction of HSCs was quantitatively evaluated. ET-1 induced a slow contraction of non-activated HSCs, which was inhibited by the non-muscle myosin II inhibitor blebbistatin, the calmodulin inhibitor W-7, and the ETA receptor antagonist ambrisentan. ET-1-induced contraction was also largely reduced in Ca2+-free conditions, but sustained contraction still remained. The tonic contraction was further diminished by the Rho-kinase inhibitor H-1152. The mRNA expression of P/Q-type voltage-dependent Ca2+ channels (VDCC), as well as STIM and Orai, constituents of store-operated channels (SOCs), was observed in mouse non-activated HSCs. ET-1-induced contraction was not affected by amlodipine, a VDCC blocker, whereas it was partly reduced by Gd3+ and amiloride, non-selective cation channel blockers. However, neither YM-58483 nor SKF-96365, which inhibit SOCs, had any effects on the contraction. These results suggest that ET-1 leads to Ca2+-influx through cation channels other than SOCs and produces myosin II-mediated contraction of non-activated HSCs via ETA receptors, as well as via mechanisms involving Ca2+-calmodulin and Rho kinase.


Sujet(s)
Phénomènes physiologiques cellulaires/effets des médicaments et des substances chimiques , Endothéline-1/pharmacologie , Cellules étoilées du foie/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Animaux , Calcium/métabolisme , Canaux calciques de type N/génétique , Canaux calciques de type N/métabolisme , Calmoduline/antagonistes et inhibiteurs , Calmoduline/métabolisme , Cellules cultivées , Antagonistes des récepteurs de l'endothéline/pharmacologie , Composés hétérocycliques avec 4 noyaux ou plus/pharmacologie , Mâle , Souris , Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/métabolisme , Phénylpropionates/pharmacologie , Pyridazines/pharmacologie , ARN messager/génétique , Récepteur de type A de l'endothéline/métabolisme , Sulfonamides/pharmacologie , rho-Associated Kinases/métabolisme
4.
Nature ; 588(7838): 521-525, 2020 12.
Article de Anglais | MEDLINE | ID: mdl-33268893

RÉSUMÉ

Myosin II is the motor protein that enables muscle cells to contract and nonmuscle cells to move and change shape1. The molecule has two identical heads attached to an elongated tail, and can exist in two conformations: 10S and 6S, named for their sedimentation coefficients2,3. The 6S conformation has an extended tail and assembles into polymeric filaments, which pull on actin filaments to generate force and motion. In 10S myosin, the tail is folded into three segments and the heads bend back and interact with each other and the tail3-7, creating a compact conformation in which ATPase activity, actin activation and filament assembly are all highly inhibited7,8. This switched-off structure appears to function as a key energy-conserving storage molecule in muscle and nonmuscle cells9-12, which can be activated to form functional filaments as needed13-but the mechanism of its inhibition is not understood. Here we have solved the structure of smooth muscle 10S myosin by cryo-electron microscopy with sufficient resolution to enable improved understanding of the function of the head and tail regions of the molecule and of the key intramolecular contacts that cause inhibition. Our results suggest an atomic model for the off state of myosin II, for its activation and unfolding by phosphorylation, and for understanding the clustering of disease-causing mutations near sites of intramolecular interaction.


Sujet(s)
Cryomicroscopie électronique , Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/ultrastructure , Animaux , Sites de fixation , Modèles moléculaires , Muscles lisses/composition chimique , Mutation , Myosine de type II/composition chimique , Myosine de type II/génétique , Phosphorylation , Liaison aux protéines , Conformation des protéines , Dépliement des protéines , Dindons
5.
Nat Commun ; 11(1): 4902, 2020 09 29.
Article de Anglais | MEDLINE | ID: mdl-32994402

RÉSUMÉ

Living cells and tissues experience various complex modes of forces that are important in physiology and disease. However, how different force modes impact gene expression is elusive. Here we apply local forces of different modes via a magnetic bead bound to the integrins on a cell and quantified cell stiffness, chromatin deformation, and DHFR (dihydrofolate reductase) gene transcription. In-plane stresses result in lower cell stiffness than out-of-plane stresses that lead to bead rolling along the cell long axis (i.e., alignment of actin stress fibers) or at different angles (90° or 45°). However, chromatin stretching and ensuing DHFR gene upregulation by the in-plane mode are similar to those induced by the 45° stress mode. Disrupting stress fibers abolishes differences in cell stiffness, chromatin stretching, and DHFR gene upregulation under different force modes and inhibiting myosin II decreases cell stiffness, chromatin deformation, and gene upregulation. Theoretical modeling using discrete anisotropic stress fibers recapitulates experimental results and reveals underlying mechanisms of force-mode dependence. Our findings suggest that forces impact biological responses of living cells such as gene transcription via previously underappreciated means.


Sujet(s)
Chromatine/composition chimique , Fibres de stress/composition chimique , Dihydrofolate reductase/génétique , Transcription génétique/physiologie , Régulation positive/physiologie , Animaux , Anisotropie , Phénomènes biomécaniques/génétique , Cellules CHO , Chromatine/métabolisme , Cricetulus , Composés hétérocycliques avec 4 noyaux ou plus/pharmacologie , Microscopie intravitale , Microscopie de fluorescence , Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/métabolisme , Fibres de stress/effets des médicaments et des substances chimiques , Fibres de stress/métabolisme , Contrainte mécanique , Transcription génétique/effets des médicaments et des substances chimiques , Régulation positive/effets des médicaments et des substances chimiques
6.
Sci Rep ; 10(1): 13341, 2020 08 07.
Article de Anglais | MEDLINE | ID: mdl-32769996

RÉSUMÉ

Subcellular dynamics of non-muscle myosin 2 (NM2) is crucial for a broad-array of cellular functions. To unveil mechanisms of NM2 pharmacological control, we determined how the dynamics of NM2 diffusion is affected by NM2's allosteric inhibitors, i.e. blebbistatin derivatives, as compared to Y-27632 inhibiting ROCK, NM2's upstream regulator. We found that NM2 diffusion is markedly faster in central fibers than in peripheral stress fibers. Y-27632 accelerated NM2 diffusion in both peripheral and central fibers, whereas in peripheral fibers blebbistatin derivatives slightly accelerated NM2 diffusion at low, but markedly slowed it at high inhibitor concentrations. In contrast, rapid NM2 diffusion in central fibers was unaffected by direct NM2 inhibition. Using our optopharmacological tool, Molecular Tattoo, sub-effective concentrations of a photo-crosslinkable blebbistatin derivative were increased to effective levels in a small, irradiated area of peripheral fibers. These findings suggest that direct allosteric inhibition affects the diffusion profile of NM2 in a markedly different manner compared to the disruption of the upstream control of NM2. The pharmacological action of myosin inhibitors is channeled through autonomous molecular processes and might be affected by the load acting on the NM2 proteins.


Sujet(s)
Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/métabolisme , Régulation allostérique/effets des médicaments et des substances chimiques , Régulation allostérique/physiologie , Animaux , Lignée cellulaire tumorale , Diffusion , Cellules HeLa , Composés hétérocycliques avec 4 noyaux ou plus/métabolisme , Humains , Rats
7.
Development ; 147(3)2020 02 04.
Article de Anglais | MEDLINE | ID: mdl-31964776

RÉSUMÉ

Directional cell intercalations of epithelial cells during gastrulation has, in several organisms, been shown to be associated with a planar cell polarity in the organisation of the actin-myosin cytoskeleton and is postulated to reflect directional tension that drives oriented cell intercalations. We have characterised and applied a recently introduced non-destructive optical manipulation technique to measure the tension in individual epithelial cell junctions of cells in various locations and orientations in the epiblast of chick embryos in the early stages of primitive streak formation. Junctional tension of mesendoderm precursors in the epiblast is higher in junctions oriented in the direction of intercalation than in junctions oriented perpendicular to the direction of intercalation and higher than in junctions of other cells in the epiblast. The kinetic data fit best with a simple viscoelastic Maxwell model, and we find that junctional tension, and to a lesser extent viscoelastic relaxation time, are dependent on myosin activity.


Sujet(s)
Cellules épithéliales/métabolisme , Gastrulation/physiologie , Jonctions intercellulaires/métabolisme , Pinces optiques , Ligne primitive/croissance et développement , Animaux , Animal génétiquement modifié , Mouvement cellulaire/physiologie , Polarité de la cellule/physiologie , Embryon de poulet , Gastrula/métabolisme , Feuillets embryonnaires/métabolisme , Protéines à fluorescence verte/génétique , Protéines à fluorescence verte/métabolisme , Hydrocarbures chlorés/pharmacologie , Microscopie de fluorescence/méthodes , Myosine de type I/antagonistes et inhibiteurs , Myosine de type I/métabolisme , Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/métabolisme , Pyrroles/pharmacologie , Transduction du signal/physiologie
8.
Biomed Pharmacother ; 122: 109775, 2020 Feb.
Article de Anglais | MEDLINE | ID: mdl-31918291

RÉSUMÉ

Arterial thrombosis (AT) causes various ischemia-related diseases, which impose a serious medical burden worldwide. As an inhibitor of myosin II, blebbistatin has an important role in thrombosis development. We investigated the effect of blebbistatin on carotid artery ligation (CAL)-induced carotid AT and its potential underlying mechanism. A model of carotid AT in mice was generated by CAL. Mice were divided into three groups: CAL model, blebbistatin-treated, and sham-operation. After 7 days, blood vessels were harvested from mice in each group. The procoagulant activity of tissue factor (TF) was tested by a chromogenic assay, and thrombus severity assessed by histopathology scores. Expression of non-muscle myosin heavy chain II A (NMMHCIIA), TF, glycogen synthase kinase 3ß (GSK3ß), and nuclear factor-kappa B (NF-κB) was detected by immunohistochemical and immunofluorescence staining. mRNA expression was measured by quantitative polymerase chain reaction. Blebbistatin (1 mg/kg) inhibited development of carotid AT, reduced infiltration of inflammatory cells, and prevented vascular-tissue damage, relative to the model group. Furthermore, blebbistatin also reduced the procoagulant activity of TF. Immunohistochemical and immunofluorescence data demonstrated that, compared with the model group, blebbistatin intervention reduced expression of NMMHCIIA, TF, GSK3ß, p65, and p-p65 in carotid-artery endothelia in the CAL-induced AT model, but it increased levels of p-GSK3ß. Blebbistatin could inhibit expression of NMMHCIIA mRNA in the CAL model. Overall, our data demonstrated that blebbistatin could inhibit TF expression and AT development in arterial endothelia (at least in part) via GSK3ß/NF-κB signaling.


Sujet(s)
Artères/effets des médicaments et des substances chimiques , Composés hétérocycliques avec 4 noyaux ou plus/pharmacologie , Myosine de type II/antagonistes et inhibiteurs , Thrombose/traitement médicamenteux , Animaux , Artères/métabolisme , Protéines du cytosquelette/métabolisme , Glycogen synthase kinase 3 beta/métabolisme , Mâle , Souris , Souris de lignée C57BL , Facteur de transcription NF-kappa B/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Thrombose/métabolisme
9.
Sci Rep ; 9(1): 18210, 2019 12 03.
Article de Anglais | MEDLINE | ID: mdl-31796850

RÉSUMÉ

The interaction of light with biological tissues has been considered for various therapeutic applications. Light-induced neurite growth has the potential to be a clinically useful technique for neuron repair. However, most previous studies used either a large illumination area to accelerate overall neurite growth or employed a light spot to guide a growing neurite. It is not clear if optical stimulation can induce the regrowth of a retracted neurite. In the present work, we used blue light (wavelength: 473 nm) to cause neurite retraction, and we proved that using a red-light (wavelength: 650 nm) spot to illuminate the soma near the junction of the retracted neurite could induce neurite regrowth. As a comparison, we found that green light (wavelength 550 nm) had a 62% probability of inducing neurite regrowth, while red light had a 75% probability of inducing neurite regrowth at the same power level. Furthermore, the neurite regrowth length induced by red light was increased by the pre-treatment with inhibitors of myosin functions. We also observed actin propagation from the soma to the tip of the re-growing neurite following red-light stimulation of the soma. The red light-induced extension and regrowth were abrogated in the calcium-free medium. These results suggest that illumination with a red-light spot on the soma may trigger the regrowth of a neurite after the retraction caused by blue-light illumination.


Sujet(s)
Lumière , Régénération nerveuse/effets des radiations , Neurites/physiologie , Actines/métabolisme , Animaux , Calcium/métabolisme , Lignée cellulaire tumorale , Couleur , Milieux de culture/métabolisme , Composés hétérocycliques avec 4 noyaux ou plus/pharmacologie , Hippocampe/cytologie , Photothérapie de faible intensité/méthodes , Souris , Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/métabolisme , Régénération nerveuse/effets des médicaments et des substances chimiques , Neurites/effets des radiations , Culture de cellules primaires/méthodes , Rats
10.
J Vis Exp ; (150)2019 08 17.
Article de Anglais | MEDLINE | ID: mdl-31475972

RÉSUMÉ

ATPase enzymes utilize the free energy stored in adenosine triphosphate to catalyze a wide variety of endergonic biochemical processes in vivo that would not occur spontaneously. These proteins are crucial for essentially all aspects of cellular life, including metabolism, cell division, responses to environmental changes and movement. The protocol presented here describes a nicotinamide adenine dinucleotide (NADH)-coupled ATPase assay that has been adapted to semi-high throughput screening of small molecule ATPase inhibitors. The assay has been applied to cardiac and skeletal muscle myosin II's, two actin-based molecular motor ATPases, as a proof of principle. The hydrolysis of ATP is coupled to the oxidation of NADH by enzymatic reactions in the assay. First, the ADP generated by the ATPase is regenerated to ATP by pyruvate kinase (PK). PK catalyzes the transition of phosphoenolpyruvate (PEP) to pyruvate in parallel. Subsequently, pyruvate is reduced to lactate by lactate dehydrogenase (LDH), which catalyzes the oxidation of NADH in parallel. Thus, the decrease in ATP concentration is directly correlated to the decrease in NADH concentration, which is followed by change to the intrinsic fluorescence of NADH. As long as PEP is available in the reaction system, the ADP concentration remains very low, avoiding inhibition of the ATPase enzyme by its own product. Moreover, the ATP concentration remains nearly constant, yielding linear time courses. The fluorescence is monitored continuously, which allows for easy estimation of the quality of data and helps to filter out potential artifacts (e.g., arising from compound precipitation or thermal changes).


Sujet(s)
Adenosine triphosphatases/antagonistes et inhibiteurs , Adenosine triphosphatases/métabolisme , Antienzymes/pharmacologie , Tests de criblage à haut débit/méthodes , NAD/métabolisme , Adénosine triphosphate/métabolisme , Animaux , Hydrolyse , Acide lactique/analyse , Acide lactique/métabolisme , Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/métabolisme , NAD/analyse , Oxydoréduction , Acide pyruvique/analyse , Acide pyruvique/métabolisme
11.
EMBO Rep ; 20(8): e47047, 2019 08.
Article de Anglais | MEDLINE | ID: mdl-31379129

RÉSUMÉ

We identify a novel endothelial membrane behaviour in transgenic zebrafish. Cerebral blood vessels extrude large transient spherical structures that persist for an average of 23 min before regressing into the parent vessel. We term these structures "kugeln", after the German for sphere. Kugeln are only observed arising from the cerebral vessels and are present as late as 28 days post fertilization. Kugeln do not communicate with the vessel lumen and can form in the absence of blood flow. They contain little or no cytoplasm, but the majority are highly positive for nitric oxide reactivity. Kugeln do not interact with brain lymphatic endothelial cells (BLECs) and can form in their absence, nor do they perform a scavenging role or interact with macrophages. Inhibition of actin polymerization, Myosin II, or Notch signalling reduces kugel formation, while inhibition of VEGF or Wnt dysregulation (either inhibition or activation) increases kugel formation. Kugeln represent a novel Notch-dependent NO-containing endothelial organelle restricted to the cerebral vessels, of currently unknown function.


Sujet(s)
Vaisseaux sanguins/cytologie , Encéphale/cytologie , Cellules endothéliales/ultrastructure , Régulation de l'expression des gènes au cours du développement , Néovascularisation physiologique/génétique , Danio zébré/embryologie , Actines/antagonistes et inhibiteurs , Actines/génétique , Actines/métabolisme , Animaux , Animal génétiquement modifié , Vaisseaux sanguins/embryologie , Vaisseaux sanguins/métabolisme , Vaisseaux sanguins/ultrastructure , Encéphale/vascularisation , Encéphale/embryologie , Encéphale/métabolisme , Composés hétérocycliques bicycliques/pharmacologie , Circulation cérébrovasculaire/génétique , Embryon non mammalien , Cellules endothéliales/métabolisme , Composés hétérocycliques avec 4 noyaux ou plus/pharmacologie , Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/génétique , Myosine de type II/métabolisme , Monoxyde d'azote/métabolisme , Organites/métabolisme , Organites/ultrastructure , Polymérisation/effets des médicaments et des substances chimiques , Récepteurs Notch/génétique , Récepteurs Notch/métabolisme , Transduction du signal , Thiazolidines/pharmacologie , Facteur de croissance endothéliale vasculaire de type A/génétique , Facteur de croissance endothéliale vasculaire de type A/métabolisme , Protéines de type Wingless/génétique , Protéines de type Wingless/métabolisme , Danio zébré/génétique , Danio zébré/métabolisme , Protéines de poisson-zèbre/génétique , Protéines de poisson-zèbre/métabolisme
12.
Biochim Biophys Acta Mol Cell Res ; 1866(12): 118516, 2019 12.
Article de Anglais | MEDLINE | ID: mdl-31348954

RÉSUMÉ

Actomyosin network under the plasma membrane of cells forms a cortical layer that regulates cellular deformations during different processes. What regulates the cortex? Characterized by its thickness, it is believed to be regulated by actin dynamics, filament-length regulators and myosin motor proteins. However, its regulation by cellular morphology (e.g. cell spread area) or mechanical microenvironment (e.g. substrate stiffness) has remained largely unexplored. In this study, super- and high-resolution imaging of actin in CHO cells demonstrates that at high spread areas (>450 µm2), the cortex is thinner, better separated as layers, and sensitive to deactivation of myosin II motors or reduction of substrate stiffness (and traction forces). In less spread cells (<400 µm2) such perturbations do not elicit a response. Myosin IIA's mechanosensing is limited here due to its lowered actin-bound fraction and higher turnover rate. Cofilin, in line with its competitive inhibitory role, is found to be overexpressed in these cells. To establish the causal relation, we initiate a spread area drop by de-adhesion and find enhanced actin dynamics and fragmentation along with oscillations and increase in thickness. This is more correlated to the reduction of traction forces than the endocytosis-based reduction in cell volume. Cortex thickness control by spread area is also found be true during differentiation of THP-1 monocytes to macrophages. Thus, we propose that spread area regulates cortex and its thickness by traction-based mechanosensing of myosin II.


Sujet(s)
Cortex cérébral/métabolisme , Myosine de type II/métabolisme , Animaux , Composés hétérocycliques bicycliques/pharmacologie , Cellules CHO , Adhérence cellulaire/effets des médicaments et des substances chimiques , Différenciation cellulaire/effets des médicaments et des substances chimiques , Cellules cultivées , Cortex cérébral/effets des médicaments et des substances chimiques , Cricetulus , Cytochalasine D/pharmacologie , Humains , Myosine de type II/antagonistes et inhibiteurs , Cellules THP-1 , Thiazolidines/pharmacologie
13.
Neurotox Res ; 35(1): 196-207, 2019 Jan.
Article de Anglais | MEDLINE | ID: mdl-30155683

RÉSUMÉ

Overactive bladder (OAB) coexists with depression in women. Here, we assessed the effects of a 1-week treatment with blebbistatin, a myosin II inhibitor, on changes in behavior and detrusor overactivity (DO) symptoms induced by a 6-week administration of 13-cis-retinoic acid (13-cis-RA), with the aid of the forced swim test (FST), spontaneous locomotor activity test, and in vivo cystometric investigations in female Wistar rats. 13-cis-RA-induced depressive-like behavior and DO symptoms were associated with increased corticotropin-releasing factor (CRF) level in the plasma, prefrontal cortex (PFC), hippocampus (Hp), Barrington's nucleus (BN), and urinary bladder. Moreover, 13-cis-RA decreased brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) levels in plasma, PFC, Hp, and BN, while it increased BDNF and NGF levels in urinary bladder. Blebbistatin exerted antidepressant-like effect and attenuated changes in the cystometric parameters as well as the central and peripheral levels of CRF, BDNF, and NGF that were induced by 13-cis-RA, while it did not affect urine production, mean, systolic or diastolic blood pressure, or heart rate. The results point to blebbistatin as a potential treatment option for OAB coexisting with depression.


Sujet(s)
Antidépresseurs/pharmacologie , Agents du système nerveux autonome/pharmacologie , Dépression/traitement médicamenteux , Composés hétérocycliques avec 4 noyaux ou plus/pharmacologie , Vessie hyperactive/traitement médicamenteux , Vessie urinaire/effets des médicaments et des substances chimiques , Animaux , Encéphale/métabolisme , Facteur neurotrophique dérivé du cerveau/métabolisme , Corticolibérine/métabolisme , Dépression/complications , Modèles animaux de maladie humaine , Femelle , Isotrétinoïne , Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/métabolisme , Facteur de croissance nerveuse/métabolisme , Répartition aléatoire , Rat Wistar , Vessie urinaire/physiopathologie , Vessie hyperactive/complications
14.
Cell Rep ; 25(3): 598-610.e5, 2018 10 16.
Article de Anglais | MEDLINE | ID: mdl-30332641

RÉSUMÉ

Despite substantial self-renewal capability in vivo, epithelial stem and progenitor cells located in various tissues expand for a few passages in vitro in feeder-free condition before they succumb to growth arrest. Here, we describe the EpiX method, which utilizes small molecules that inhibit PAK1-ROCK-Myosin II and TGF-ß signaling to achieve over one trillion-fold expansion of human epithelial stem and progenitor cells from skin, airway, mammary, and prostate glands in the absence of feeder cells. Transcriptomic and epigenomic studies show that this condition helps epithelial cells to overcome stresses for continuous proliferation. EpiX-expanded basal epithelial cells differentiate into mature epithelial cells consistent with their tissue origins. Whole-genome sequencing reveals that the cells retain remarkable genome integrity after extensive in vitro expansion without acquiring tumorigenicity. EpiX technology provides a solution to exploit the potential of tissue-resident epithelial stem and progenitor cells for regenerative medicine.


Sujet(s)
Cellules épithéliales/cytologie , Myosine de type II/antagonistes et inhibiteurs , Bibliothèques de petites molécules/pharmacologie , Cellules souches/cytologie , Facteur de croissance transformant bêta/antagonistes et inhibiteurs , p21-Activated Kinases/antagonistes et inhibiteurs , rho-Associated Kinases/antagonistes et inhibiteurs , Animaux , Différenciation cellulaire , Prolifération cellulaire , Cellules cultivées , Cellules épithéliales/effets des médicaments et des substances chimiques , Cellules épithéliales/métabolisme , Cellules nourricières/cytologie , Cellules nourricières/effets des médicaments et des substances chimiques , Cellules nourricières/métabolisme , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Humains , Techniques in vitro , Kératinocytes/cytologie , Kératinocytes/effets des médicaments et des substances chimiques , Kératinocytes/métabolisme , Myosine de type II/génétique , Myosine de type II/métabolisme , Tumeurs/traitement médicamenteux , Tumeurs/métabolisme , Tumeurs/anatomopathologie , Transduction du signal , Cellules souches/effets des médicaments et des substances chimiques , Cellules souches/métabolisme , Facteur de croissance transformant bêta/génétique , Facteur de croissance transformant bêta/métabolisme , Tests d'activité antitumorale sur modèle de xénogreffe , p21-Activated Kinases/génétique , p21-Activated Kinases/métabolisme , rho-Associated Kinases/génétique , rho-Associated Kinases/métabolisme
15.
J Med Chem ; 61(21): 9410-9428, 2018 11 08.
Article de Anglais | MEDLINE | ID: mdl-29878759

RÉSUMÉ

( S)-Blebbistatin, a chiral tetrahydropyrroloquinolinone, is a widely used and well-characterized ATPase inhibitor selective for myosin II. The central role of myosin II in many normal and pathological biological processes has been revealed with the aid of this small molecule. The first part of this manuscript provides a summary of myosin II and ( S)-blebbistatin literature from a medicinal chemist's perspective. The second part of this perspective deals with the physicochemical deficiencies that trouble the use of ( S)-blebbistatin in advanced biological settings: low potency and solubility, fluorescence interference, (photo)toxicity, and stability issues. A large toolbox of analogues has been developed in which particular shortcomings have been addressed. This perspective provides a necessary overview of these developments and presents guidelines for selecting the best available analogue for a given application. As the unmet need for high-potency analogues remains, we also propose starting points for medicinal chemists in search of nanomolar myosin II inhibitors.


Sujet(s)
Découverte de médicament/méthodes , Composés hétérocycliques avec 4 noyaux ou plus/pharmacologie , Myosine de type II/antagonistes et inhibiteurs , Animaux , Chimie pharmaceutique , Composés hétérocycliques avec 4 noyaux ou plus/composition chimique , Humains
16.
Proc Natl Acad Sci U S A ; 115(9): E1991-E2000, 2018 02 27.
Article de Anglais | MEDLINE | ID: mdl-29444861

RÉSUMÉ

Electron microscope studies have shown that the switched-off state of myosin II in muscle involves intramolecular interaction between the two heads of myosin and between one head and the tail. The interaction, seen in both myosin filaments and isolated molecules, inhibits activity by blocking actin-binding and ATPase sites on myosin. This interacting-heads motif is highly conserved, occurring in invertebrates and vertebrates, in striated, smooth, and nonmuscle myosin IIs, and in myosins regulated by both Ca2+ binding and regulatory light-chain phosphorylation. Our goal was to determine how early this motif arose by studying the structure of inhibited myosin II molecules from primitive animals and from earlier, unicellular species that predate animals. Myosin II from Cnidaria (sea anemones, jellyfish), the most primitive animals with muscles, and Porifera (sponges), the most primitive of all animals (lacking muscle tissue) showed the same interacting-heads structure as myosins from higher animals, confirming the early origin of the motif. The social amoeba Dictyostelium discoideum showed a similar, but modified, version of the motif, while the amoeba Acanthamoeba castellanii and fission yeast (Schizosaccharomyces pombe) showed no head-head interaction, consistent with the different sequences and regulatory mechanisms of these myosins compared with animal myosin IIs. Our results suggest that head-head/head-tail interactions have been conserved, with slight modifications, as a mechanism for regulating myosin II activity from the emergence of the first animals and before. The early origins of these interactions highlight their importance in generating the inhibited (relaxed) state of myosin in muscle and nonmuscle cells.


Sujet(s)
Myosine de type II/antagonistes et inhibiteurs , Actines/composition chimique , Adénosine triphosphate/composition chimique , Motifs d'acides aminés , Animaux , Évolution biologique , Calcium/composition chimique , Lignée cellulaire , Biologie informatique , Cryomicroscopie électronique , Dictyostelium , Traitement d'image par ordinateur , Insectes , Microscopie électronique , Myosine de type II/composition chimique , Phosphorylation , Porifera , Liaison aux protéines , Schizosaccharomyces , Scyphozoa , Anémones de mer , Dindons
17.
Biochemistry ; 56(41): 5526-5538, 2017 10 17.
Article de Anglais | MEDLINE | ID: mdl-28898058

RÉSUMÉ

SM22α, also named transgelin, is an actin filament-associated protein in smooth muscle and fibroblasts. Three decades after its discovery, the biological function of SM22α remains under investigation. Here we report a novel finding that the expression and degradation of SM22α/transgelin are regulated by mechanical tension. Following a mass spectrometry identification of SM22α degradation in isolated and tension-unloaded mouse aorta, we developed specific monoclonal antibodies to study the regulation of SM22α in human fetal lung myofibroblast line MRC-5 and primary cultures of neonatal mouse skin fibroblasts. The level of SM22α is positively related to the mechanical tension in the cytoskeleton produced by the myosin II motor in response to the stiffness of the culture matrix. Quantitative reverse transcription polymerase chain reaction demonstrated that the expression of SM22α is regulated at the transcriptional level. This mechanical regulation resembles that of calponin 2, another actin filament-associated protein. Immunofluorescent staining co-localized SM22α with F-actin, myosin, and calponin 2 in mouse skin fibroblasts. The close phylogenetic relationship between SM22α and the calponin family supports that SM22α is a calponin-like regulatory protein. The level of SM22α is decreased in skin fibroblasts isolated from calponin 2 knockout mice, suggesting interrelated regulation and function of the two proteins. On the other hand, SM22α expression was maximized at a matrix stiffness higher than that for calponin 2 in the same cell type, indicating differentiated regulation and tension responsiveness. The novel mechanoregulation of SM22α/transgelin lays the groundwork for understanding its cellular functions.


Sujet(s)
Cytosquelette/métabolisme , Matrice extracellulaire/métabolisme , Régulation de l'expression des gènes , Kératinocytes/métabolisme , Protéines des microfilaments/métabolisme , Protéines du muscle/métabolisme , Myofibroblastes/métabolisme , Animaux , Marqueurs biologiques/métabolisme , Protéines de liaison au calcium , Calpain/métabolisme , Lignée cellulaire , Cellules cultivées , Cytosquelette/composition chimique , Cytosquelette/effets des médicaments et des substances chimiques , Antienzymes/pharmacologie , Matrice extracellulaire/composition chimique , Matrice extracellulaire/effets des médicaments et des substances chimiques , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Composés hétérocycliques avec 4 noyaux ou plus/pharmacologie , Humains , Kératinocytes/cytologie , Kératinocytes/effets des médicaments et des substances chimiques , Souris de lignée C57BL , Souris knockout , Souris transgéniques , Protéines des microfilaments/génétique , Protéines du muscle/génétique , Myofibroblastes/cytologie , Myofibroblastes/effets des médicaments et des substances chimiques , Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/métabolisme , Spécificité d'organe , Flexibilité , Transport des protéines/effets des médicaments et des substances chimiques ,
18.
Proc Natl Acad Sci U S A ; 114(36): 9529-9534, 2017 09 05.
Article de Anglais | MEDLINE | ID: mdl-28827333

RÉSUMÉ

Active transport in the cytoplasm plays critical roles in living cell physiology. However, the mechanical resistance that intracellular compartments experience, which is governed by the cytoplasmic material property, remains elusive, especially its dependence on size and speed. Here we use optical tweezers to drag a bead in the cytoplasm and directly probe the mechanical resistance with varying size a and speed V We introduce a method, combining the direct measurement and a simple scaling analysis, to reveal different origins of the size- and speed-dependent resistance in living mammalian cytoplasm. We show that the cytoplasm exhibits size-independent viscoelasticity as long as the effective strain rate V/a is maintained in a relatively low range (0.1 s-1 < V/a < 2 s-1) and exhibits size-dependent poroelasticity at a high effective strain rate regime (5 s-1 < V/a < 80 s-1). Moreover, the cytoplasmic modulus is found to be positively correlated with only V/a in the viscoelastic regime but also increases with the bead size at a constant V/a in the poroelastic regime. Based on our measurements, we obtain a full-scale state diagram of the living mammalian cytoplasm, which shows that the cytoplasm changes from a viscous fluid to an elastic solid, as well as from compressible material to incompressible material, with increases in the values of two dimensionless parameters, respectively. This state diagram is useful to understand the underlying mechanical nature of the cytoplasm in a variety of cellular processes over a broad range of speed and size scales.


Sujet(s)
Cytoplasme/composition chimique , Cytoplasme/physiologie , Adénosine triphosphate/métabolisme , Animaux , Phénomènes biomécaniques , Cytoplasme/effets des médicaments et des substances chimiques , Cytosquelette/composition chimique , Élasticité , Cellules épithéliales/cytologie , Cellules HeLa/cytologie , Composés hétérocycliques avec 4 noyaux ou plus/pharmacologie , Humains , Rein/cytologie , Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/métabolisme , Pinces optiques , Rats , Viscosité
19.
Stem Cell Reports ; 9(2): 419-428, 2017 08 08.
Article de Anglais | MEDLINE | ID: mdl-28793244

RÉSUMÉ

There has been increasing success with the generation of pancreatic cells from human induced pluripotent stem cells (hiPSCs); however, the molecular mechanisms of the differentiation remain elusive. The purpose of this study was to reveal novel molecular mechanisms for differentiation to PDX1+NKX6.1+ pancreatic endoderm cells, which are pancreatic committed progenitor cells. PDX1+ posterior foregut cells differentiated from hiPSCs failed to differentiate into pancreatic endoderm cells at low cell density, but Rho-associated kinase (ROCK) or non-muscle myosin II (NM II) inhibitors rescued the differentiation potential. Consistently, the expression of phosphorylated myosin light chain 2 and NM IIA was downregulated in aggregation culture. Notably, the soluble factors we tested were substantially effective only with ROCK-NM II inhibition. The PDX1+NKX6.1+ cells induced with NM II inhibitors were successfully engrafted and maturated in vivo. Taken together, these results suggest that NM IIs play inhibitory roles for the differentiation of hiPSCs to pancreatic endoderm cells.


Sujet(s)
Différenciation cellulaire , Endoderme/embryologie , Cellules souches pluripotentes induites/cytologie , Cellules souches pluripotentes induites/métabolisme , Myosine de type II/métabolisme , Pancréas/embryologie , rho-Associated Kinases/métabolisme , Animaux , Marqueurs biologiques , Lignée cellulaire , Cellules cultivées , Endoderme/cytologie , Endoderme/métabolisme , Régulation de l'expression des gènes , Protéines à homéodomaine/génétique , Protéines à homéodomaine/métabolisme , Humains , Mâle , Souris , Modèles biologiques , Myosine de type II/antagonistes et inhibiteurs , Pancréas/cytologie , Pancréas/métabolisme , ARN messager/génétique , ARN messager/métabolisme , Transduction du signal , rho-Associated Kinases/antagonistes et inhibiteurs
20.
Biochem Biophys Res Commun ; 490(3): 849-854, 2017 08 26.
Article de Anglais | MEDLINE | ID: mdl-28648599

RÉSUMÉ

2,3-Butandione 2-monoxime (BDM) is a widely used myosin inhibitor with an unclear mode of action. In this report, we investigated the mechanism of BDM oxime group nucleophilic reactivity on the phosphoester bond of ATP. BDM increased the ATPase activity of skeletal myosin subfragment 1 (S1) under conditions in which ATP cleavage is the rate-limiting step (K+, EDTA-ATPase activity of native S1 and Mg2+-ATPase activity of trinitrophenylated S1 and partially unfolded S1). Furthermore, the effect of BDM on the S1-bound adenosine 5'-(ß,γ-imido) triphosphate (AMPPNP) 31P NMR spectrum suggests that BDM changes the microenvironment around the phosphorus atoms of myosin-bound nucleotide. A computational search for the BDM-binding site in the adenosine 5'-[γ-thio] triphosphate (myosin-ATPγS) complex predicted that BDM is located adjacent to the nucleotide on myosin. Therefore, we propose that the BDM oxime group catalytically assists in ATP cleavage, thereby enhancing the ATPase activity of myosin in a manner analogous to pralidoxime-mediated reactivation of organophosphate-inactivated acetylcholinesterase. This is the first study suggesting that oxime provides catalytic assistance for ATP cleavage by an ATP-hydrolyzing enzyme.


Sujet(s)
Adénosine triphosphate/métabolisme , Myosine de type II/antagonistes et inhibiteurs , Myosine de type II/métabolisme , Oximes/composition chimique , Oximes/pharmacologie , Adenosine triphosphatases/métabolisme , Animaux , Ca(2+) Mg(2+)-ATPase/métabolisme , Simulation de docking moléculaire , Sous-fragments de myosine/métabolisme , Lapins
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...